Experimental CAR-T therapy takes on progressive MS
NCT ID NCT06138132
First seen Feb 28, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This early-stage trial tests a personalized cell therapy called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not responding to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy certain immune cells (B cells) that may drive MS. The study will enroll 12 adults aged 18-65 and primarily check for safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Multiple Sclerosis Center
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KYV-101 CAR-T cell therapy (a personalized immune cell treatment) plus bendamustine (a chemotherapy drug to prepare the body)
What this could lead to
If successful, this could point toward a new way to slow or stop worsening disability in progressive multiple sclerosis by targeting faulty immune cells.
What could go wrong
This is a very early Phase 1 trial with only 12 people, focused on safety. The therapy may cause serious side effects like cytokine release syndrome or nerve problems, and it is not yet known if it will help the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.